By Josh Beckerman
Biohaven shares slipped after the Food and Drug Administration extended the Prescription Drug User Fee Act date for the biopharmaceutical company's troriluzole application by three months.
The stock was down 8.5%, to $17.99, after hours Wednesday and has dropped about 47% since the start of the year.
The FDA's Division of Neurology 1 also informed the New Haven, Conn., company that it plans to hold an advisory committee meeting, but no date has been scheduled. The FDA didn't raise any new concerns in its letter.
Biohaven now expects an FDA decision in the fourth quarter.
Troriluzole is a potential treatment for spinocerebellar ataxia, a group of inherited neurodegenerative disorders.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
May 14, 2025 19:10 ET (23:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。